Protara Therapeutics (TARA) News Today → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free TARA Stock Alerts $2.83 -0.04 (-1.39%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHC Wainwright Equities Analysts Decrease Earnings Estimates for Protara Therapeutics, Inc. (NASDAQ:TARA)americanbankingnews.com - May 9 at 6:48 AMProtara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - May 8 at 1:18 AMBuy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002markets.businessinsider.com - May 7 at 12:30 AMTARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024investorplace.com - May 2 at 1:06 PMProtara Therapeutics: Q1 Earnings Snapshotsfgate.com - May 2 at 8:35 AMProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Updateglobenewswire.com - May 2 at 8:00 AMProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54msn.com - April 17 at 12:11 PMProtara Therapeutics, Inc. (TARA)finance.yahoo.com - April 15 at 6:45 PMBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatmentmarkets.businessinsider.com - April 9 at 2:25 AMProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equitymsn.com - April 5 at 3:10 PMProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloridemarkets.businessinsider.com - April 5 at 10:10 AMProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Upmarkets.businessinsider.com - April 5 at 10:10 AMProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financingglobenewswire.com - April 5 at 8:04 AMProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutritionglobenewswire.com - April 5 at 8:02 AMProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCglobenewswire.com - April 5 at 8:00 AM3 Stocks That Could Help You Retire on a Private Islandinvestorplace.com - March 23 at 6:00 AMBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunitymarkets.businessinsider.com - March 13 at 6:27 PMProtara Therapeutics: Q4 Earnings Snapshotchron.com - March 13 at 1:26 PMProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 8:00 AMTARA Aug 2024 7.500 callfinance.yahoo.com - March 3 at 11:42 PMTARA May 2024 2.500 putfinance.yahoo.com - March 3 at 11:42 PMProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short Interestmarketbeat.com - March 1 at 1:38 PMNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024theglobeandmail.com - February 28 at 7:58 PMProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 8:00 AMNorthSea Therapeutics commences Phase IIa trial for IFALD therapymsn.com - February 22 at 7:53 PMWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Ratefinance.yahoo.com - February 17 at 8:43 AMCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionalityseekingalpha.com - January 25 at 3:04 PMOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)markets.businessinsider.com - December 2 at 7:37 PMProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncologyfinance.yahoo.com - November 30 at 12:38 PMProtara Therapeutics Stock (NASDAQ:TARA) Earnings Dates and Earning Callsbenzinga.com - November 5 at 1:52 PMProtara Therapeutics reports Q3 resultsmsn.com - November 5 at 12:01 AMProtara Therapeutics files for $300M mixed shelfmsn.com - November 3 at 2:21 PMProtara Therapeutics Inc (TARA) Announces Q3 2023 Financial Resultsfinance.yahoo.com - November 3 at 2:21 PMProtara Therapeutics Announces Third Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - November 3 at 9:20 AMProtara begins dosing in Phase II lymphatic malformation cell therapy trialmsn.com - October 24 at 5:04 AMProtara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformationsfinance.yahoo.com - October 23 at 9:02 AMNon Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)benzinga.com - October 7 at 1:33 AMHere's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situationfinance.yahoo.com - September 10 at 5:44 PMProtara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 5:44 PMH.C. Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)markets.businessinsider.com - August 4 at 7:41 PMHC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendationmsn.com - August 4 at 7:41 PMProtara Therapeutics (TARA) Price Target Decreased by 6.96% to 32.03msn.com - August 3 at 4:59 PMProtara Therapeutics Announces Second Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - August 3 at 11:58 AMTARA - Protara Therapeutics, Inc.finance.yahoo.com - July 14 at 3:40 PMUS74365U1079.SG - Protara Therapeutics Inc.finance.yahoo.com - June 11 at 5:25 PMH.C. Wainwright Remains a Buy on Kamada (KMDA)markets.businessinsider.com - May 25 at 7:47 AMH.C. Wainwright Sticks to Their Buy Rating for Bellerophon (BLPH)markets.businessinsider.com - May 17 at 10:05 AMH.C. Wainwright Keeps Their Buy Rating on Keros Therapeutics (KROS)markets.businessinsider.com - May 8 at 7:15 AMAnalysts Are Bullish on These Healthcare Stocks: Veru (VERU), Viking Therapeutics (VKTX)markets.businessinsider.com - May 8 at 7:15 AMRecap: Protara Therapeutics Q1 Earningsmsn.com - May 4 at 3:10 PM Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! TARA Media Mentions By Week TARA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼0.750.36▲Average Medical News Sentiment TARA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼70▲TARA Articles Average Week Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INKT News SRZN News NKGN News INAB News ACHL News PLUR News SABS News DYAI News CYTH News BCLI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society“Crash Insurance” For Your RetirementUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.